Short-Circuiting Gene Regulatory Networks: Origins of B Cell Lymphoma

Trends in Genetics

Volumn 31, Issue 12, 2015, Pages 720-731

  Koues, Olivia I ^a   Oltz, Eugene M ^a   Payton, Jacqueline E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIS ACTING ELEMENT; DNA; HISTONE; UNTRANSLATED RNA;

B CELL LYMPHOMA; B CELL LYMPHOMA CELL; CARCINOGENESIS; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE REGULATORY NETWORK; GENE SEQUENCE; GENETIC VARIABILITY; HISTONE MODIFICATION; HUMAN; INHERITANCE; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; GENETIC EPIGENESIS; GENETICS; MOUSE;

ANIMALS; EPIGENESIS, GENETIC; GENE REGULATORY NETWORKS; HUMANS; LYMPHOMA, B-CELL; MICE;

EID: 84950125820     PISSN: 01689525     EISSN: 13624555     Source Type: Journal    
DOI: 10.1016/j.tig.2015.09.006     Document Type: Review

References (124)

1. Alizadeh A.A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
2. Rosenwald A., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. 2001, 194:1639-1647.
3. Klein U., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. 2001, 194:1625-1638.
4. Rosenwald A., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
5. Dave S.S., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 2004, 351:2159-2169.
6. Staudt L.M., Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv. Immunol. 2005, 87:163-208.
7. Miyazaki K., et al. The establishment of B versus T cell identity. Trends Immunol. 2014, 35:205-210.
8. Murphy K.M., et al. Janeway Immunologie 2009, Springer Spektrum, (in German).
9. Victora G.D., et al. Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood 2012, 120:2240-2248.
10. De Silva N.S., Klein U. Dynamics of B cells in germinal centres. Nat. Rev. Immunol. 2015, 15:137-148.
11. Basso K., Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nat. Rev. Immunol. 2015, 15:172-184.
12. Shaffer A.L., et al. Pathogenesis of human B cell lymphomas. Annu. Rev. Immunol. 2012, 30:565-610.
13. Young R.M., et al. B cell receptor signaling in diffuse large B cell lymphoma. Semin. Hematol. 2015, 52:77-85.
14. Koues O.I., et al. Enhancer sequence variants and transcription factor deregulation synergize to construct pathogenic regulatory circuits in B cell lymphoma. Immunity 2015, 42:186-198.
15. Lanasa M.C. Novel insights into the biology of CLL. Hematol. Am. Soc. Hematol. Educ. Program 2010, 2010:70-76.
16. Campo E., Rule S. Mantle cell lymphoma: evolving management strategies. Blood 2015, 125:48-55.
17. Bianchi G., Munshi N.C. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 2015, 125:3049-3058.
18. Küppers R. New insights in the biology of Hodgkin lymphoma. Hematol. Am. Soc. Hematol. Educ. Program 2012, 2012:328-334.
19. Bernstein B.E., et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:57-74.
20. Roadmap Epigenomics Consortium, et al. Integrative analysis of 111 reference human epigenomes. Nature 2015, 518:317-330.
21. Andersson R., et al. An atlas of active enhancers across human cell types and tissues. Nature 2014, 507:455-461.
22. Thurman R.E., et al. The accessible chromatin landscape of the human genome. Nature 2012, 489:75-82.
23. Whyte W.A.A., et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 2013, 153:307-319.
24. Herz H-M., et al. Enhancer malfunction in cancer. Mol. Cell 2014, 53:859-866.
25. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
26. Akhtar-Zaidi B., et al. Epigenomic enhancer profiling defines a signature of colon cancer. Science 2012, 336:736-739.
27. Chapuy B., et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013, 24:777-790.
28. Jones P.A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 2012, 13:484-492.
29. Heyn H., et al. DNA methylation contributes to natural human variation. Genome Res. 2013, 23:1363-1372.
30. Solary E., et al. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 2014, 28:485-496.
31. Im A.P., et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014, 28:1774-1783.
32. Morin R.D., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
33. Pasqualucci L., et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471:189-195.
34. Lohr J.G., et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:3879-3884.
35. Landau D.A., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013, 152:714-726.
36. Beà S., et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:18250-18255.
37. Kulis M., et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat. Genet. 2012, 44:1236-1242.
38. Martín-Subero J.I., et al. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 2009, 113:2488-2497.
39. O'Riain C., et al. Array-based DNA methylation profiling in follicular lymphoma. Leukemia 2009, 23:1858-1866.
40. Shaknovich R., et al. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood 2010, 116:e81-e89.
41. Chambwe N., et al. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood 2014, 123:1699-1708.
42. Queirós A.C., et al. A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. Leukemia 2014, 29:598-605.
43. Pan H., et al. Epigenomic evolution in diffuse large B-cell lymphomas. Nat. Commun. 2015, 6:6921.
44. Landau D.A., et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell 2014, 26:813-825.
45. Gruber M., Wu C.J. Evolving understanding of the CLL genome. Semin. Hematol. 2014, 51:177-187.
46. Jiang Y., Melnick A. The epigenetic basis of diffuse large B-cell lymphoma. Semin. Hematol. 2015, 52:86-96.
47. Kishimoto W., Nishikori M. Molecular pathogenesis of follicular lymphoma. J. Clin. Exp. Hematol. 2014, 54:23-30.
48. Okosun J., et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat. Genet. 2013, 46:176-181.
49. Bödör C., et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013, 122:3165-3168.
50. Morin R.D., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42:181-185.
51. Yap D.B., et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011, 117:2451-2459.
52. Béguelin W., et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013, 23:677-692.
53. Velichutina I., et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010, 116:5247-5255.
54. Berg T., et al. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood 2014, 123:3914-3924.
55. Pasqualucci L., et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014, 6:130-140.
56. Bereshchenko O.R., et al. Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet. 2002, 32:606-613.
57. Lill N.L., et al. Binding and modulation of p53 by p300/CBP coactivators. Nature 1997, 387:823-827.
58. Ogryzko V.V., et al. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996, 87:953-959.
59. Kung A.L., et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev. 2000, 14:272-277.
60. Hatzi K., et al. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell Rep. 2013, 4:578-588.
61. Zhang J., et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood 2014, 123:2988-2996.
62. Corradin O., et al. Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. Genome Res. 2014, 24:1-13.
63. Khurana E., et al. Integrative annotation of variants from 1092 humans: application to cancer genomics. Science 2013, 342:1235587.
64. Maurano M.T., et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012, 337:1190-1195.
65. Zhou X., et al. Epigenomic annotation of genetic variants using the Roadmap Epigenome Browser. Nat. Biotechnol. 2015, 33:345-346.
66. Leung D., et al. Integrative analysis of haplotype-resolved epigenomes across human tissues. Nature 2015, 518:350-354.
67. Cerhan J.R., et al. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat. Genet. 2014, 46:1233-1238.
68. Farh K.K-H., et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 2014, 518:337-343.
69. Berndt S.I., et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat. Genet. 2013, 45:868-876.
70. Cowper-Sal Lari R., et al. Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat. Genet. 2012, 44:1191-1198.
71. Huang Q., et al. A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. Nat. Genet. 2014, 46:126-135.
72. Yao L., et al. Functional annotation of colon cancer risk SNPs. Nat. Commun. 2014, 5:5114.
73. Kridel R., et al. Pathogenesis of follicular lymphoma. J. Clin. Invest. 2012, 122:3424-3431.
74. Love C., et al. The genetic landscape of mutations in Burkitt lymphoma. Nat. Genet. 2012, 44:1321-1325.
75. Polak P., et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature 2015, 518:360-364.
76. Qian J., et al. B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. Cell 2014, 159:1524-1537.
77. Morris K.V., Mattick J.S. The rise of regulatory RNA. Nat. Rev. Genet. 2014, 15:423-437.
78. Holoch D., Moazed D. RNA-mediated epigenetic regulation of gene expression. Nat. Rev. Genet. 2015, 16:71-84.
79. St.Laurent G., et al. The Landscape of long noncoding RNA classification. Trends Genet. 2015, 31:239-251.
80. Fatica A., Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat. Rev. Genet. 2014, 15:7-21.
81. Batista P.J., Chang H.Y. Long noncoding RNAs: cellular address codes in development and disease. Cell 2013, 152:1298-1307.
82. Hausser J., Zavolan M. Identification and consequences of miRNA-target interactions - beyond repression of gene expression. Nat. Rev. Genet. 2014, 15:599-612.
83. De Yébenes V.G., et al. Regulation of B-cell development and function by microRNAs. Immunol. Rev. 2013, 253:25-39.
84. De Yébenes V.G., et al. miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J. Exp. Med. 2008, 205:2199-2206.
85. Xiao C., et al. miR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007, 131:146-159.
86. Ventura A., et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008, 132:875-886.
87. Musilova K., Mraz M. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia 2015, 29:1004-1017.
88. Eis P.S., et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:3627-3632.
89. Cui B., et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood 2014, 124:546-554.
90. Zhao J-J., et al. MicroRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010, 115:2630-2639.
91. Roehle A., et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br. J. Haematol. 2008, 142:732-744.
92. Rodriguez A., et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007, 316:608-611.
93. Thai T-H., et al. Regulation of the germinal center response by microRNA-155. Science 2007, 316:604-608.
94. Vigorito E., et al. MicroRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007, 27:847-859.
95. Dorsett Y., et al. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-IgH translocation. Immunity 2008, 28:630-638.
96. Tan L.P., et al. miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab. Invest. 2009, 89:708-716.
97. Rai D., et al. Targeting of SMAD5 links microRNA-155 to the TGF-β pathway and lymphomagenesis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:3111-3116.
98. Jiang D., Aguiar R.C.T. MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-β1/SMAD5 signaling module. Blood 2014, 123:86-93.
99. Klein U., et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010, 17:28-40.
100. Baumjohann D., Ansel K.M. MicroRNA regulation of the germinal center response. Curr. Opin. Immunol. 2014, 28:6-11.
101. Chen C-Z., et al. Regulation of immune responses and tolerance: the microRNA perspective. Immunol. Rev. 2013, 253:112-128.
102. Derrien T., et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012, 22:1775-1789.
103. Guttman M., Rinn J.L. Modular regulatory principles of large non-coding RNAs. Nature 2012, 482:339-346.
104. Cabili M.N., et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011, 25:1915-1927.
105. Meng F-L., et al. Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability. Cell 2014, 159:1538-1548.
106. Ranzani V., et al. The long intergenic noncoding RNA landscape of human lymphocytes highlights the regulation of T cell differentiation by linc-MAF-4. Nat. Immunol. 2015, 16:318-325.
107. Sehgal L., et al. FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia 2014, 28:2376-2387.
108. Peng W., et al. Upregulation of long noncoding RNA PEG10 associates with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenicity. Clin. Exp. Med. 2015, Published online April 12, 2015. 10.1007/s10238-015-0350-9.
109. Blume C.J., et al. p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. Leukemia 2015, Published online May 14, 2015. 10.1038/leu.2015.119.
110. Huarte M., et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010, 142:409-419.
111. Crump M., et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann. Oncol. 2008, 19:964-969.
112. Falkenberg K.J., Johnstone R.W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 2014, 13:673-691.
113. Lwin T., et al. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J. Clin. Invest. 2013, 123:4612-4626.
114. McCabe M.T., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
115. Garapaty-Rao S., et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem. Biol. 2013, 20:1329-1339.
116. Lovén J., et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
117. Mertz J.A., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16669-16674.
118. Delmore J.E., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
119. Filippakopoulos P., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
120. Trabucco S.E., et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin. Cancer Res. 2015, 21:113-122.
121. Wilber A., et al. A zinc-finger transcriptional activator designed to interact with the gamma-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts. Blood 2010, 115:3033-3041.
122. Gilbert L.A., et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 2013, 154:442-451.
123. Perez-Pinera P., et al. Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nat. Methods 2013, 10:239-242.
124. Hilton I.B., et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat. Biotechnol. 2015, 33:510-517.